Elsevier

European Urology

Volume 75, Issue 1, January 2019, Pages 184-192
European Urology

Platinum Priority – Case Series of the Month
Editorial by Alicia K. Morgans on pp. 193–194 of this issue
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency

https://doi.org/10.1016/j.eururo.2018.09.048Get rights and content
Under a Creative Commons license
open access

Abstract

Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, and that such genomic aberrations are synthetically lethal with both poly(ADP)-ribose polymerase inhibition and platinum, has increased interest in the utilisation of these drugs against a subset of these diseases. Here in we report three patients with advanced castration-resistant PCa with HRD defects having exceptional responses to carboplatin.

Keywords

Prostate cancer
Homologous recombination defects
Platinum
DNA repair genes

Cited by (0)